Mutant p53 may compromise the response to docetaxel, and ADT+docetaxel compared to ADT alone might not confer a survival benefit in patients with AVPC-TSG-altered PCa (defined by a transcriptional signature), but these are very preliminary data and need to be validated. Here, TP53 is linked to posterior cortical atrophy.